Your browser doesn't support javascript.
Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.
Ghasemiyeh, Parisa; Borhani-Haghighi, Afshin; Karimzadeh, Iman; Mohammadi-Samani, Soliman; Vazin, Afsaneh; Safari, Anahid; Qureshi, Adnan I.
  • Ghasemiyeh P; Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Borhani-Haghighi A; Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Karimzadeh I; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mohammadi-Samani S; Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Vazin A; Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Safari A; Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Qureshi AI; Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Ther Clin Risk Manag ; 16: 595-605, 2020.
Article in English | MEDLINE | ID: covidwho-646401
ABSTRACT
Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug-drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Reviews Language: English Journal: Ther Clin Risk Manag Year: 2020 Document Type: Article Affiliation country: Tcrm.S259152

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Reviews Language: English Journal: Ther Clin Risk Manag Year: 2020 Document Type: Article Affiliation country: Tcrm.S259152